NCT01235442View on ClinicalTrials.gov

Evaluate Efficacy, and Safety of Topical Therapy and Etanercept in Subjects With Moderate to Severe Plaque Psoriasis

PHASE3CompletedINTERVENTIONAL
Enrollment

592

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

October 31, 2011

Study Completion Date

December 31, 2011

Conditions
Psoriasis
Interventions
DRUG

1=Etanercept

50 mg SC bi-weekly for 12 weeks followed by 50 mg SC weekly for 12 weeks.

DRUG

2=Clobetasol propionate foam

0.05% clobetasol propionate foam applied topically twice daily during two up-to-2 week courses

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
collaborator

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

lead

Amgen

INDUSTRY